The company said its officers will reaffirm adjusted shareholders' earnings for full year 2026 of at least $25.50 per diluted share in meetings with investors and analysts over the next week.

1. 01

   The company said its officers will reaffirm adjusted shareholders' earnings for full year 2026 of at least $25.50 per diluted share in meetings with investors and analysts over the next week.

2. 02

   Elevance Health said it will also reaffirm its 2026 benefit expense ratio guidance of 90.2%, plus or minus 50 basis points.

3. 03

   The company said it was notified by CMS on February 27, 2026 of its intent to impose sanctions suspending enrollment of Medicare beneficiaries into its Medicare Advantage-Prescription Drug plans and suspending certain communication activities to Medicare beneficiaries, effective as of March 31, 2026. The company said its guidance includes the impact of these sanctions if they are imposed.

4. 04

   The company said it cannot reasonably estimate the impact of any potential financial payments to resolve this matter on its GAAP diluted shareholders' earnings per share for full year 2026, so it is unable to provide a reconciliation of its adjusted diluted earnings per share guidance for full year 2026 to the most directly comparable GAAP measure without unreasonable effort.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.